Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study

Chiun‐Sheng Huang, Youngsen Yang, Ava Kwong, Shin‐Cheh Chen, Ling‐Ming Tseng, Mei-Ching Liu, Kunwei Shen, Shusen Wang, Ting‐Ying Ng, Yi Feng, Guofang Sun, Iris R.F. Yan, Zhimin Shao